What AlphaGenome means for genomics, and why interpretation still matters

This month, Google DeepMind published a landmark paper in Nature introducing AlphaGenome, a deep learning model that promises a more unified way to predict genomic function from DNA sequence alone (“sequence-to-function”). The model analyzes up to one million base pairs at a time and simultaneously predicts thousands of functional genomic signals, including gene expression, chromatin features, and splicing, across diverse biological modalities.

AlphaGenome’s release marks an important step in computational genomics. By combining long-sequence context with base-pair resolution, it outperforms most existing specialized models and offers a single framework for assessing variant effects across a wide range of regulatory outcomes. This is not just a new tool, but a proof of concept that integrating multiple layers of genomic biology into one predictive model is possible, and even practical for researchers to explore.

So why does this matter?

1. AI is closing the gap on sequence-to-function prediction

Historically, one of the persistent bottlenecks in genomics has been the sheer complexity of reading the “grammar” of DNA: beyond the ~2% that codes for proteins lies the non-coding majority, the so-called dark genome, where most regulatory elements reside. AlphaGenome makes major strides here, predicting regulatory behavior across millions of bases at once rather than in isolated segments.

That has implications for foundational biology, hypothesis generation, and early discovery, especially when researchers are hunting down the functional consequences of non-coding variation or attempting to understand how far-flung parts of the genome interact in regulatory networks.

2. But prediction is not interpretation

This is where it’s important to distinguish raw computational capability from clinical and biological interpretation.

AlphaGenome predicts how sequence changes might influence genomic signals. It doesn’t, by itself, tell you what those changes mean for a specific patient, a disease, a drug target, or a diagnostic decision. It can suggest hypotheses, and powerful ones, but turning those hypotheses into action requires more than a model output.

That’s why services like enGenome’s eVai interpretation platform remain essential.

Our platform focuses on translating genomic data into actionable insight by:

• Annotating variants with known clinical and functional evidence
• Integrating genomic and phenotype data to assess relevance in context
• Mapping predictions to curated biological knowledge bases
• Flagging actionable variants that matter for drug discovery or diagnostics

AlphaGenome can tell you that a variant may alter a genomic signal, but our work helps you understand what that alteration means in context, for a disease pathway, a therapeutic hypothesis, or a clinical interpretation. Raw predictions need interpretation layers, evidence weighting, and biological grounding before they can inform real-world decisions.

3. AI models accelerate discovery but data diversity and clinical validation still matter

One of the greatest values of models like AlphaGenome is speed and scale. They allow researchers to simulate and prioritize hypotheses across huge genomic landscapes much faster than traditional experimental biology. But they also depend on the quality and diversity of training data.

Real-world genomes vary across populations, tissues, and disease states. Laboratory data and clinical cohorts often reveal patterns that purely computational models may miss, particularly when environmental, epigenetic, or population-specific factors influence gene regulation. That’s why:

• Clinical validation in diverse cohorts remains essential
• Integration with experimental and phenotypic data is critical for accuracy
• Regulatory interpretation and evidence standards cannot be automated alone

AlphaGenome is a powerful sequence-to-function accelerator for functional genomics and discovery teams, but it is not, by design, a clinical interpretation engine. In other words, models like AlphaGenome and human-designed interpretation platforms are complementary, not interchangeable.

4. The future is hybrid: AI tools + expert annotation

AlphaGenome’s emergence underscores a broader shift: genomics is becoming computational first, biology second, but not biology redundant. That’s because understanding DNA is not just about deciphering patterns, it’s about connecting those patterns to disease mechanisms, clinical outcomes, and actionable insights.

At enGenome, our approach is to meet AI where it is strongest (large-scale prediction) and bring in domain expertise where it matters most (interpretation, validation, and clinical actionability). We see AlphaGenome and similar tools as powerful partners in:

• Prioritizing variants for deeper analysis
• Generating biological hypotheses at scale
• Reducing time to insight in research and discovery
• Augmenting, not replacing, expert interpretation workflows

Conclusion

AlphaGenome is an impressive demonstration of what AI can do with DNA sequence alone, and a signpost for the future of genomics research. But the path from sequence to biomedical truth is not one that a model can walk alone. It requires layers of interpretation, evidence synthesis, clinical validation, and domain expertise to translate predictions into meaningful impact.

As we embrace these new tools, the most successful strategies will be hybrid, combining the power of AI models with the rigour of curated interpretation and biological context. That’s where the next wave of breakthroughs will come, and where platforms like eVai from enGenome will continue to play a crucial role.